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ABSTRACT
Objectives To characterise and risk- stratify patients 
presenting to a heart failure (HF) clinic according to the 
National Institute for health and Care Excellence (NICE) 
algorithm.
Methods This is an observational study of prospectively 
collected data in the Sheffield HEArt Failure registry of 
consecutive patients with suspected HF between April 
2012 and January 2020. Outcome was defined as all- 
cause mortality.
Results 6144 patients were enrolled: 71% had HF and 
29% had no HF. Patients with N- terminal pro- brain- type 
natriuretic peptide (NT- proBNP) >2000 pg/mL were 
more likely to have HF than those with NT- proBNP of 
400–2000 pg/mL (92% vs 64%, respectively). Frequency 
of HF phenotypes include: HF with preserved ejection 
fraction (HFpEF) (33%), HF with reduced ejection fraction 
(HFrEF) (29%), HF due to valvular heart disease (4%), HF 
due to pulmonary hypertension (5%) and HF due to right 
ventricular systolic dysfunction (1%). There were 1485 
(24%) deaths over a maximum follow- up of 6 years. The 
death rate was higher in HF versus no HF (11.49 vs 7.29 
per 100 patient- years follow- up, p<0.0001). Patients with 
HF and an NT- proBNP >2000 pg/mL had lower survival 
than those with NT- proBNP 400–2000 pg/mL (3.8 years vs 
5 years, p<0.0001). Propensity matched survival curves 
were comparable between HFpEF and HFrEF (p=0.88).
Conclusion Our findings support the use by NICE’s HF 
diagnostic algorithm of tiered triage of patients with 
suspected HF based on their NT- proBNP levels. The two 
pathways yielded distinctive groups of patients with varied 
diagnoses and prognosis. HFpEF is the most frequent 
diagnosis, with its challenges of poor prognosis and 
paucity of therapeutic options.
INTRODUCTION
Heart failure (HF) is common (26 million 
patients worldwide) and is one of the 
leading causes of morbidity and mortality.1 
HF predominantly affects people aged 50 
years and beyond,2 and adversely affects 
patients’ quality of life and survival. It poses 
an economic burden on the National Health 
Service of the UK.3 Early and accurate diag-
nosis and management of HF are paramount 
to alleviate symptoms, improve prognosis 
and lead to more cost- effective healthcare 
delivery.4
Key questions
What is already known about this subject?
 ► Since the publication of the Chronic Heart Failure 
National Institute for health and Care Excellence 
(NICE) guidelines of 2010, which was updated 
in 2018, there was no published demonstration 
of its application in the real world until this year 
2020. Recently, colleagues from Portsmouth and 
Southampton published their experience with the 
application of the diagnostic algorithm of these 
guidelines in a smaller cohort than ours. Their expe-
rience suggested that 53% of the patients presented 
with N- terminal pro- brain- type natriuretic peptide 
(NT- proBNP) >2000 pg/mL. The diagnostic yield 
of NICE’s NT- proBNP threshold in their cohort was 
55%, much lower than expected from the research 
literature. They found no difference in the survival 
between those with and without heart failure.
What does this study add?
 ► Our study reports on an almost 8- year experience 
with a large consecutive cohort of patients reflecting 
the incidence of heart failure in the community in 
Sheffield, an English city with 551 800 inhabitants. 
We believe that our findings provide an insight into 
the real- world incidence of heart failure in the com-
munity, and demonstrate the value of the diagnostic 
algorithm suggested by NICE guidelines.
 ► Our study showed the diagnostic yield of NICE’s 
NT- proBNP threshold (400 pg/mL) is 71%, with the 
majority of the patients presenting with NT- pro BNP 
of 400–2000 pg/mL. The study provides an insight 
into the survival rate of the different heart failure 
phenotypes and looks into the impact of the height 
of NT- proBNP, the symptom burden stipulated by the 
New York Heart Association functional class and the 
stages of chronic kidney disease on the prognosis. 
The study showed that there is no difference in the 
survival rate between those with heart failure and 
reduced or preserved ejection fraction, similar to 
the experience shown in acute heart failure setting 
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The National Institute for health and Care Excel-
lence (NICE) produced a diagnostic algorithm for 
the patients suspected of HF.5 Thus, patients are 
referred for transthoracic echocardiography (TTE) 
and specialist assessment based on clinical presenta-
tion and measurement of N- terminal pro- brain- type 
natriuretic peptide (NT- proBNP). The diagnostic 
algorithm recommends patients are seen and assessed 
within 2 weeks if NT- proBNP >2000 pg/mL and within 
6 weeks if NT- proBNP is 400–2000 pg/mL.5
Although the guidelines were published 10 years 
ago, limited data are available on the performance 
of the diagnostic algorithm.6 Reliable and contempo-
rary description and characterisation of the popula-
tion with HF is important to develop insight into HF 
trends, recognise clinical outcomes, and to improve 
and shape both current services and future clinical HF 
pathways.
The main objectives of this study are: first, to char-
acterise real- world patients presenting to a HF clinic 
serving the city of Sheffield in the UK; second, to 
stratify patients whose diagnosis followed the estab-
lished NICE HF diagnostic algorithm; and finally, 
to explore and investigate predictors of all- cause 
mortality in subphenotypes of HF defined in line with 




Patients suspected of HF from a population of 551 800 
are screened by their general practitioners (GPs) 
using a single measurement of NT- proBNP. In accord-
ance with NICE guidelines, those with symptoms and/
or signs suggestive of HF and a raised NT- proBNP 
(threshold 400 pg/mL) are referred to the HF clinic 
in Sheffield.5 7 Data were collected prospectively and 
electronically encrypted with an annual data valida-
tion check. The analytical cohort was derived from all 
patients presenting to this HF clinic between 13 April 
2012 and 31 January 2020. The inclusion criteria were: 
age 18 years or over, raised NT- proBNP (>400 pg/mL) 
and symptoms and/or signs suggestive of HF. Exclu-
sion criteria were: incomplete TTE study, or absence 
of NT- proBNP measurement.
HF assessment
All patients referred to the HF clinic by their GPs with 
NT- proBNP >400 pg/mL underwent a resting 12- lead 
ECG and TTE. Each patient was clinically assessed by 
a specialist. The final diagnosis was determined by the 
HF specialist integrating the presenting history, clinical 
examination and the results of investigations in keeping 
with NICE guidelines.5 8
The patients with HF were subdivided into five pheno-
types: HF with preserved ejection fraction (HFpEF), 
HF with reduced ejection fraction (HFrEF), HF due to 
pulmonary hypertension (HF- PH) where the only cardiac 
abnormality is pulmonary artery pressure of >40 mm Hg, 
HF due to right ventricular systolic dysfunction (HF- 
RVSD) where the only cardiac abnormality is the systolic 
impairment of the right ventricle, and HF due to valvular 
heart disease (HF- VHD) where severe valvular disease is 
the only abnormality responsible for the syndrome of HF. 
It is recognised that pulmonary hypertension, RVSD and 
severe valvular disease could coexist with either HFrEF 
or HFpEF. In those circumstances, the patients were 
assigned as having HFrEF or HFpEF, respectively.
Study variables
Clinical and TTE variables are detailed in online supple-
mental file. The 12- lead ECG documented: rhythm (sinus, 
atrial fibrillation, atrial flutter or paced), QRS duration, 
left axis deviation, ST/T- wave changes, presence of 
ectopic beats, any conduction delays or atrioventricular 
blocks and presence of leftventricle (LV) hypertrophy 
using the standard voltage criteria.9 Similarly, details of 
the TTE findings were recorded in the database.
Statistical analysis
Statistical analyses were performed in MedCalc V.19.0.5. 
Categorical baseline characteristics are described with 
numbers and percentages. Continuous variables are 
described using means and SD. Comparison of continuous 
variables was done using an independent t- test, while the 
comparison of categorical variables was done using Χ2 t- test. 
Mortality rates are presented as per 100 patient- years (100PY) 
of follow- up (FU). Kaplan- Meier (KM) curves were used to 
visualise and interpret the data of variables associated with 
mortality. KM curves used the log- rank test to investigate the 
differences in curves between alive and dead patients at FU. 
Further survival analysis was done using propensity score 
matching for all clinical demographics which demonstrated 
association to all- cause mortality. In addition to propen-
sity matched score method, we also tested the difference 
of survival curves between HFpEF and HFrEF using Cox’s 
proportional hazard model.10 The Kruskal- Wallis one- way 
analysis of variance test was used to investigate the overall 
differences in clinical characteristics, the New York Heart 
Association (NYHA) symptom burden and chronic kidney 
disease (CKD) distribution of different subphenotypes of 
HF. All tests were two- sided, and statistical significance was 
considered if p value was <0.05.
Key questions
How might this impact on clinical practice?
 ► The data we provide demonstrate the prominence of heart failure 
with preserved left ventricular ejection fraction as the most com-
mon diagnosis encountered in the community. This particular syn-
drome remains deprived of any evidence- based effective therapy. 
This calls on the medical and scientific community to concentrate 
the efforts into further research into the patho- physiology, preven-
tion and treatment of the patients with this heart failure phenotype.
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RESULTS
Patient characteristics
The demographic data and patient characteristics 
are summarised in tables 1 and 2. In almost 8 years’ 
duration, 6272 patients were assessed in our HF clinic. 
From the total cohort, 128 (2%) patients had other 
disorders (non- cardiac such as pulmonary fibrosis 
and cancer, and cardiovascular such as atrial arrhyth-
mias, and pure valvular disease such as aortic stenosis 
without HF) and were excluded from further anal-
ysis. The study cohort was thus 6144 patients. Of this 
referred cohort of patients, 4368 patients (71%) were 
diagnosed with HF and 1776 patients (29%) did not 
have HF. Patients with HF were older (80±9 years vs 
78±9 years, p<0.01), had higher mean NT- proBNP 
levels (2593±8918 pg/mL vs 946±810 pg/mL, p<0.01) 
and had higher NYHA functional class (2.3±0.7 vs 
1.8±0.7, p<0.01) than the patients with no HF. Women 
comprised 54% of those with HF. For the total popu-
lation, the mean NT- proBNP was 2114.4±7501 pg/mL.
Compared with the patients with no HF, those with 
HF had higher prevalence of comorbidities such as 
systemic hypertension (65% p=0.032), CKD (60% 
p<0.01) and ischaemic heart disease (36% p<0.01). 
Similarly, more patients with HF had VHD, previous 
myocardial infarction (MI), diabetes mellitus (DM) 
and hypercholesterolaemia (p<0.01). Nearly one- third 
of the referred patients were smokers (28% of those 
with no HF vs 38% of those with HF). On the other 
hand, there was no statistically significant difference 
in the incidence of chronic obstructive pulmonary 
disease (COPD) between patients with HF and without 
HF. Surprisingly, obesity was not a statistically signifi-
cant comorbidity in any of the phenotypes of patients 
with HF.
NT-proBNP >2000pg/mL vs NT-proBNP 400–2000pg/mL
Patients with NT- proBNP >2000 pg/mL, using the 2- week 
pathway of the diagnostic algorithm, were 1624 patients 




Age (years) 78±9 80±9 <0.01
NT- proBNP 946±810 2593±8918 <0.01
Gender (male) 764 (43%) 1999 (46%) 0.05
Ischaemic heart disease 406 (23%) 1565 (36%) <0.01
Valvular heart disease 127 (7%) 1042 (24%) <0.01
Previous myocardial infarction 125 (7%) 701 (16%) <0.01
Obesity 57 (3%) 189 (4%) 0.043
Hypertension 1110 (63%) 2856 (65%) 0.032
Diabetes mellitus 307 (17%) 982 (22%) <0.01
Hypercholesterolaemia 300 (17%) 906 (21%) <0.01
Chronic obstructive pulmonary 
disease
328 (18%) 806 (18%) 0.988
Dementia 18 (1%) 79 (2%) 0.023
Smoker 507 (29%) 1358 (31%) 0.049
Cerebrovascular accident 189 (11%) 598 (14%) <0.01
Chronic kidney disease (II–V) 886 (50%) 2621 (60%) <0.01
New York Heart Association 
functional class
1.8±0.7 2.3±0.7 <0.01
HF, heart failure; NT- proBNP, N- terminal pro- brain- type 
natriuretic peptide.
Table 2 Patient characteristics in various heart failure subcategorisations
  HFpEF HFrEF HF- VHD HF- PH HF- RVSD χ² P value
n 2022 1759 240 289 58
Age (years) 81±8 78±10 81±9 78±10 79±9 <0.01
NT- proBNP 1780±3111 3603±13 450 2698±3628 2104±2588 2309±5051 <0.01
Sex (male) 684 (34%) 1057 (60%) 93 (39%) 128 (44%) 37 (64%) 274 <0.01
IHD 552 (27%) 881 (50%) 54 (23%) 66 (23%) 12 (21%) 265 <0.01
VHD 354 (18%) 398 (23%) 220 (92%) 53 (18%) 17 (29%) 660 <0.01
MI 179 (9%) 473 (27%) 21 (9%) 22 (8%) 6 (10%) 257 <0.01
Obesity 100 (5%) 64 (4%) 11 (5%) 12 (4%) 2 (3%) 4 0.39
Hypertension 1469 (73%) 1022 (58%) 141 (59%) 192 (66%) 32 (55%) 96 <0.01
Diabetes mellitus 493 (24%) 381 (22%) 43 (18%) 54 (19%) 11 (19%) 11 0.03
Hypercholesterolaemia 473 (23%) 357 (20%) 28 (12%) 41 (14%) 7 (12%) 31 <0.01
COPD 347 (17%) 309 (18%) 37 (15%) 98 (34%) 15 (26%) 53 <0.01
Dementia 35 (2%) 33 (2%) 3 (1%) 8 (3%) 0 (0%) 3 0.54
Smoker 654 (32%) 519 (30%) 63 (26%) 108 (37%) 14 (24%) 13 0.01
CVA 277 (14%) 255 (14%) 29 (12%) 30 (10%) 7 (12%) 4 0.36
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; HF, heart failure; HFpEF, heart failure with preserved ejection 
fraction; HFrEF, heart failure with reduced ejection fraction; IHD, ischaemic heart disease; MI, myocardial infarction; NT- proBNP, N- terminal 
pro- brain- type natriuretic peptide; PH, pulmonary hypertension; RVSD, right ventricular systolic dysfunction; VHD, valvular heart disease.
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(26.4% of the referred cohort). The remaining 4520 
patients (73.6%), who had NT- proBNP 400–2000 pg/mL, 
used the 6- week pathway.
Patients with NT- proBNP >2000 pg/mL had a 
higher chance of having HF compared with those with 
NT- proBNP of 400–2000 pg/mL (92% vs 64%, respec-
tively) (figure 1). Patients with HFpEF were similarly 
distributed between the 2- week and 6- week pathways 
(31% and 34%, respectively). The similarity in distribu-
tion between those with NT- proBNP of 400–2000 pg/mL 
and those with NT- proBNP >2000 pg/mL was also noted 
in those with HF- PH, HF- VHD and those with HF- RVSD. 
On the other hand, HFrEF was the single most common 
HF diagnosis (50%) among the patients with NT- proBNP 
of >2000 pg/mL.
Phenotypes of HF
Table 2 shows the characteristics of the five phenotypes 
of the population with HF. Patients with HFrEF are signif-
icantly younger than patients with HFpEF and patients 
with HF- VHD. Of the 6144 referred cohort, HFpEF was 
the most common phenotype seen in 2022 patients 
(33%), whereas HFrEF affected 1759 patients (29%). 
Patients with HFpEF had a lower mean NT- proBNP 
levels (1780±311 pg/mL) than those with HFrEF 
(3603±1345 pg/mL) or HF- VHD (2698±362 pg/mL). 
Male patients predominated among those with HFrEF 
(60%) and with HF- RVSD (64%). There was female 
predominance in those with HFpEF (66%), HF- VHD 
(61%) or HF- PH (56%).
Symptom burden in HF phenotypes
With an increase in HF symptom burden, HFrEF, HF- PH 
and HF- RVSD become more prevalent (p<0.0001) 
(figure 2A). HF- RVSD and HF- PH are more common in 
the patients presenting in NYHA functional class IV than 
those presenting in NYHA functional classes I–III. HFpEF 
is the diagnosis of the largest group of patients with 
NYHA classes I and II (48% and 49%, respectively), while 
representing only 23% of those presenting with NYHA 
functional class IV. This suggests that the majority of the 
patients with HFpEF have milder symptoms. In contrast, 
HFrEF is the diagnosis in 50% of the patient cohort in 
NYHA functional class IV.
The HF phenotypes in different stages of renal dysfunction 
(CKD)
HFpEF was the diagnosis of 74% of the patients with HF 
and CKD stage V (figure 2B). In contrast, patients with 
HFrEF constituted 34%–43% of those with the other 
CKD stages. However, it is important to note that of the 
complete cohort, CKD stage V only represented 0.6% of 
the population (online supplemental figure 1). Thus, 
the observed increased incidence of HFpEF in CKD V is 
unlikely to have an impact on the outcomes of the cohort.
Survival analysis
Of the referred cohort, there were 1485 (24%) deaths 
over a maximum FU period of 6 years (mean FU 2.3±2 
years). The death rate was significantly higher in patients 
with HF (11.5 (95% CI 11 to 12.2) vs 7.3 (95% CI 6.5 to 
8.2) per 100PY, p<0.0001).
The all- cause mortality as measured per 100PY of the 
patients with HF demonstrated an ascending order of the 
HF phenotypes: HFpEF (10.3 (95% CI 9.4 to 11.3) per 
100PY), HFrEF (11.8 (95% CI 10.8 to 12.8) per 100PY), 
HF- RVSD (13.3 (95% CI 7.5 to 22) per 100PY), HF- VHD 
(15 (95% CI 11.8 to 18.7) per 100PY) and the highest was 
Figure 1 Final diagnosis in heart failure clinics for the whole population. (A) Histogram of the number of patients in each 
category of diagnosis. From a total of 6144 patients seen in the HF clinic, 29% of patients did not have HF. (B) In patients with 
NT- proBNP > 2000pg/ml, HFrEF was the main presenting diagnosis (50%) which was followed by HFpEF (31%).HF, heart 
failure; HFpEF, HF with preserved ejection fraction; HF- PH, HF with pulmonary hypertension; HFrEF, HF with reduced ejection 
fraction; HF- RVSD, HF with right ventricular systolic dysfunction; HF- VHD, HF with valvular heart disease; NT- proBNP, N- 
terminal pro- brain- type natriuretic peptide.
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HF- PH (15.7 (95% CI 12.9 to 19) per 100PY). There was 
no statistically significant difference between the mortality 
of those with HF- PH, HF- VHD or HF- RVSD. However, the 
differences were significant between those with HFpEF and 
HFrEF; and between each of those and the categories with 
the highest mortality (HF- PH and HF- VHD) (figure 3). The 
median age for those with HFpEF was 81±8 years of age 
and the median age of those with HFrEF being 78±10 years 
of age (p<0.01). However, since the patients with HFrEF 
are not particularly young, this difference may not have a 
significant biological difference.
On KM analysis, the survival curves were wide apart 
between those with no HF versus the patients with HF over 
the long- term FU period (χ2=47.14, p<0.0001) (figure 4A). 
Whereas, the survival curves were not significantly different 
between HFpEF and HFrEF (χ2=3.63, p=0.06).
Patients with HF and an NT- proBNP ≥2000 pg/mL 
had significantly worse survival rate than patients with 
lower NT- proBNP levels (3.8 years vs 5 years, χ2=173.5, 
p<0.0001) (figure 5).
Worsening NYHA functional class was similarly associ-
ated with worsening mean survival (NYHA I: 4.8 years; 
NYHA II: 4.9 years; NYHA III: 4.2 years and NYHA IV: 
2.47 years, χ2=221.3, p<0.0001) (figure 5B). On KM anal-
ysis, the obvious deterioration in survival rate started 
with NYHA functional class III and became marked with 
NYHA functional class IV.
For comparing patients with HF versus those with no 
HF, and for comparing those with HFpEF versus those 
with HFrEF, the following covariates demonstrated associ-
ation to outcome and were used in propensity matching: 
age, NT- proBNP level, male gender, obesity, hyperten-
sion, DM, hypercholesterolaemia, COPD, dementia, 
VHD, MI, stroke and renal impairment.
When comparing the survival of patients in different 
NYHA functional classes, all of the above variables were 
included for propensity matching, except NT- proBNP 
level that was replaced by phenotype diagnosis.
Figure 2 Stacked histogram demonstrating the percentage of patients with a specific HF diagnosis in each category of NYHA 
and CKD stage. (A) Patients with HFpEF were predominantly in NYHA functional class I/II, versus patients with HFrEF, who 
were predominantly in NYHA functional class IV. (B) HF patients with a diagnosis of HFpEF were more likely to have worse CKD 
stage than any other type of HF diagnosis. CKD, chronic kidney disease; HFpEF, heart failure with preserved ejection fraction; 
HF- PH, heart failure with pulmonary hypertension; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart 
Association; RVSD, right ventricular systolic dysfunction; VHD, valvular heart disease
Figure 3 Incidence of all- cause mortality in each sub- 
phenotype of heart failure per 100 patient- years. Statistical 
significant changes to other groups are highlighted with 
letters representing the specific group. The lines represent 
the 95% confidence interval. HF, heart failure; HFpEF, HF 
with preserved ejection fraction; HF- PH, HF with pulmonary 
hypertension; HFrEF, HF with reduced ejection fraction; 
HF- RVSD, HF with right ventricular systolic dysfunction; HF- 
VHD, HF with valvular heart disease.
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Post- propensity matching, the differences between the 
survival curves were less for the comparison of patients 
with no HF versus patients with HF than those seen on 
KM analysis before propensity matching, but remained 
statistically significantly different (χ2=18.46, p<0.0001) 
(figure 4C). The survival curves of HFpEF and HFrEF 
almost overlap demonstrating no actual difference in 
survival over time (χ2=0.02, p=0.88) (figure 4D). By 
adjusting for covariates using the Cox’s proportional 
hazard model, the survival trend was worse for HFrEF, 
but this again remained statistically not significant 
(figure 6). The differences in survival curves remained 
statistically significantly different for both NT- proBNP 
and NYHA functional class after propensity matching 
(figure 5).
DISCUSSION
Our study sought to characterise the patients referred 
from the community to the HF clinic using NICE diag-
nostic algorithm5 and to investigate their outcomes. Until 
this year 2020, these have remained largely untested.
We prospectively entered all patients referred to the 
HF clinic into the SHEAF registry.11 We excluded the 
few patients before 2013 whose entry into the diagnostic 
algorithm was through a history of MI. We observed that 
Figure 4 Kaplan- Meier survival curves. (A and B) Survival comparison of patients with versus without HF and with HFpEF 
versus HFrEF, over a follow- up period of up to 6 years. (C and D) Propensity matched survival comparison of patients with 
versus without HF and with HFpEF versus HFrEF, over a follow- up period of up to 6 years. HF, heart failure; HFpEF, HF with 
preserved ejection fraction; HFrEF, HF with reduced ejection fraction.
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GPs tended to test the NT- proBNP even when there was 
a history of MI. Zheng et al6 made a similar observation 
to ours. The majority of the patients with a history of MI 
referred to our HF clinic in that first year had NT- proBNP 
levels <2000 pg/mL. Thus, these patients were entered 
into the 6- week pathway. We have amended the protocol 
making raised NT- proBNP as the single port of entry into 
the diagnostic HF service. This modification was subse-
quently adopted by NICE in the chronic HF guidelines 
(NG106-2018).7
The most common phenotype of HF in the community 
patients in the SHEAF registry was HFpEF. Indeed, one 
of the step changes in the HF NICE guidelines (CG108) 
of 2010 was the introduction of the almost universal use 
of natriuretic peptides (NPs) by GPs as the main port of 
entry into the HF diagnostic algorithm.5 This key inves-
tigation to access HF diagnostic services in secondary 
care is based on its high specificity at the thresholds 
chosen.12 13 Prior to those guidelines, many cases of 
HFpEF were undiagnosed. Within the diagnostic algo-
rithm, the referred patients are triaged into a 2- week and 
6- week pathways based on the level of the NPs. This was 
due to the poor short- term and medium- term outcomes 
shown in patients with HF and very high NP levels.14 
Figure 5 Kaplan- Meier survival curves. (A and B) Survival comparison of patients with NTproBNP 400- 1999pg/ml versus 
≥NTproBNP 400- 1999pg/ml, and in different NYHA functional status, over a follow- up period of up to 6 years. (C and D) 
Propensity matched survival comparison of patients with NTproBNP 400- 1999pg/ml versus ≥NTproBNP 400- 1999pg/ml, and 
in different NYHA functional status, over a follow- up period of up to 6 years. NT- proBNP, N- terminal pro- brain- type natriuretic 
peptide; NYHA, New York Heart Association.
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Thus, patients with NT- proBNP >2000 pg/mL have their 
TTE and see the specialist within 2 weeks, while those 
with NT- proBNP 400–2000 pg/mL have the TTE and the 
specialist’s review within 6 weeks. Providing patients with 
early specialist review to ensure the correct diagnosis is 
made and the appropriate management plan is imple-
mented are known to improve outcomes.9
The HF NICE guidelines of 2010 (CG108) and of 2018 
(NG106) chose the diagnostic threshold for NT- proBNP 
at 400 pg/mL. This is at variance with the European 
Society of Cardiology (ESC) threshold of 125 pg/
mL.15 16 The ESC approach is based on ruling out HF, 
at the expense of low specificity at that threshold. This 
approach can potentially overwhelm echocardiography 
services and specialist clinics.17 The cost- effectiveness of 
NICE approach of using NT- proBNP as a gatekeeper for 
the diagnosis of HF has been further confirmed by the 
work of Taylor et al.7 17
We recognise that elevated NT- proBNP is an indepen-
dent risk factor for cardiovascular events and mortality 
in the general population.18 Indeed, we demonstrated 
that those with no HF (29%) suffered mortality rate at 
7.3 (95% CI 6.5 to 8.2) per 100PY. We have published the 
clinical predictors of mortality in this group of people.11 
The patients diagnosed with HF had a significantly higher 
mortality rate of 11.5 (95% CI 11 to 12.2) per 100PY.
Biomarkers of myocardial fibrosis in patients with 
chronic HF (soluble ST2 receptor, galectin-3 and high 
sensitivity cardiac troponin) were proposed as additives 
to NP in aiding prognostication of patients with HF.19–21 
Whether we adopt novel cardiac biomarkers as an adjunct 
to NT- proBNP in the triage or prognostication process 
remains to be seen.
Among our cohort of 6144 patients, 26.4% entered 
the 2- week pathway (NT- proBNP >2000 pg/mL), while 
73.6% entered the algorithm via the 6- week pathway 
(NT- proBNP 400–2000 pg/mL). Those percentages 
follow a natural distribution pattern, but are at odds with 
those of Zheng et al6 as 53% of their patients used the 
2- week pathway.
In our cohort, 71% of the patients with NT- proBNP 
>400 pg/mL had HF, which is close to the expected yield 
of diagnostic studies that formed the basis of NICE’s 
choice of that threshold.5 7 13 Furthermore, there was 
a higher diagnostic yield (92%) with the NT- proBNP 
>2000 pg/mL versus a diagnostic yield of 64% when 
NT- proBNP is 400–2000 pg/mL. It was interesting to 
note that in their recently published study, Zheng et al6 
reported a low diagnostic yield of the same NT- proBNP 
threshold of >400 pg/mL at only 55%.
While our study and that of Zheng et al6 have imple-
mented the same diagnostic algorithm by NICE,5 our 
results appear to reflect potentially different incidence 
of HF in the community. Their two centres serve a 
population of 1 175 000 people. Portsmouth and South-
ampton contributed to their study for 35 months and 
24 months, respectively. Their 1271 referrals suggested 
that Southampton received 2 referrals/100 000/month, 
and Portsmouth received 4 referrals/100 000/month. In 
contrast, in Sheffield we serve a population of 551 800, 
and received 6144 referrals in 93 months, at a mean rate 
of 12 referrals/100 000/month.
Notwithstanding the differences between our findings 
and those by Zheng et al, it is important to recognise that 
observational studies like ours and theirs are significantly 
affected by the epidemiological differences related to 
the different characteristics of the populations each of 
our groups serves, and the impact of referral patterns by 
primary care.
Unsurprisingly, the survival analysis of our larger 
registry showed the mortality rate is higher among our 
patients with HF versus those with no HF table 3(figure 4). 
While the two groups were similar in age and comorbid-
ities, the main difference between them is the presence 
of any form of HF. Taylor et al22 published a population- 
based cohort study in the UK from primary care data of 
55 959 new diagnoses of HF over 17 years. The survival 
trends were significantly worse at 1 year, 5 years and 10 
years in the HF versus no HF groups. These findings are 
consistent with what we observed in the SHEAF registry. 
In contrast, Zheng et al6 reported no difference in the 
survival between the HF versus no HF groups, which is 
surprising.
Other findings of interest are the impact on the prog-
nosis of both the degree of rise in the NT- proBNP and 
the severity of symptoms at presentation as defined by 
the NYHA class. Those presenting with NT- proBNP 
>2000 pg/mL survived on average 1.2 year less than 
those presenting with NT- proBNP of 400–2000 pg/mL. 
Figure 6 Kaplan- Meier curves comparing HFpEF and 
HFrEF survival. These curves have been adjusted for 
covariates using the Cox’s proportional- hazards regression. 
CKD, chronic kidney disease; COPD, chronic obstructive 
pulmonary disease; HFpEF, heart failure with preserved 
ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; MI; myocardial infarction; NT- proBNP, N- terminal 
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Heart failure and cardiomyopathies
Similarly, there was a 2.33 years difference in survival 
between those with NYHA functional class I at presenta-
tion and those presenting with NYHA functional class IV.
We have confirmed the findings of others23 as we 
demonstrated that those with HF- PH have an even higher 
mortality than those with HFpEF or HFrEF (figure 3).
Those who emphasise the impact of lower left ventric-
ular ejection fraction (LVEF) on survival feel that 
patients with HFrEF should have higher mortality than 
those with HFpEF. Others may attach more emphasis on 
the impact of comorbidities such as advanced CKD or 
characteristics such as ageing. A third group may believe 
that the absence of effective therapy for patients with 
HFpEF should increase their mortality rate compared 
with the patients with HFrEF. In our study, the mortality 
at 100PY FU showed statistically significant difference 
between those with HFpEF and those with HFrEF. 
However, when we adjusted for covariates using the 
Cox’s proportional hazard model (figure 6), the KM 
survival curves showed no statistically significant differ-
ence between the two groups. As our dataset is a large 
one, we have appropriately used propensity matched 
analysis representing real data instead of adjusting for 
the mean of covariates. The latter method produced KM 
survival curves of HFpEF and HFrEF that almost over-
lapped demonstrating no actual difference in survival 
over time (figure 4D). Thus, we confirmed there is no 
statistically significant difference between the survival 
of patients with these two phenotypes of HF over a 
maximum FU of 6 yearstable 3.
Not unlike our findings, Ambrosy et al24 showed that 
while there is a trend toward lower in- hospital mortality 
among hospitalised patients with HF with HFpEF in the 
Get With The Guidelines- HF programme, FU data from 
the Organized Program to Initiate Lifesaving Treat-
ment in Hospitalized Patients With HF registry suggest 
that post- discharge survival is poor irrespective of EF. In 
other words, when one extends the FU beyond the first 
3 months, one would be surprised to find similar survival 
in both groups. Similarly, Varela- Roman et al demon-
strated no effect of LVEF on the survival.25
These are similar to other studies including the results 
from the UK HF national audit. An older cohort studied 
between 1987 and 2001 showed small differences in the 
mortality of patients with HFpEF and patients with HFrEF, 
at 1 and 5 years (29% vs 32%, and 65% vs 68%, respec-
tively).26 The latter series predates the impact of major 
advances in therapeutics for HFrEF, with beta- blockers 
and mineralocorticoid antagonists. Thus, the improved 
survival of patients with HFrEF coupled with absence 
of disease- modifying therapy for HFpEF27 allowed the 
outcomes of these two phenotypes of HF to become 
similar.
We propose that a UK- wide diagnostic HF registry is 
established along the lines we established in the SHEAF 
registry in Sheffield. This will require several conditions 
to be met as described in a recent editorial in Heart.28
Clinical perspective
This is the largest published registry of an HF clinic in the 
UK and is the second description of the implementation 
of the diagnostic algorithm of NICE HF guidelines.5 7 
The prospective entry of data by specialists in HF, and 
the fact the clinic serves the whole population of patients 
with suspected HF in one city improves our confidence 
that the characterisation of the patients enrolled is a true 
representation of such a population.
Limitations
There are four limitations: we are uncertain that all 
the patients reporting symptoms of HF were tested and 
referred, we do not know if there were patients suspected 
of HF with raised NT- proBNP who were not referred to 
the service, there were patients whose HF diagnosis was 
made when they were admitted acutely with HF bypassing 
our clinic, and finally we have not been able to provide 
detailed analysis of patients without complete TTE due 
to lack of data.
CONCLUSION
Our findings support the use by NICE’s HF diagnostic 
algorithm of tiered triage of patients with suspected 
HF based on their NT- proBNP levels. The two pathways 
yielded distinctive groups of patients with varied diag-
noses and prognoses. We recognise the eminence of 
HFpEF as the most frequent diagnosis, with its challenges 
of poor prognosis and paucity of therapeutic options. 
This demands of all of us to work harder to investigate 
the pathophysiology, course and potential management 
of HFpEF.
Twitter Hosamadin Assadi @HosamAssadi and Abdallah Al- Mohammad @
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